ImmunityBio (NASDAQ:IBRX) Stock Price Down 11.5%
ImmunityBio (NASDAQ:IBRX) Stock Price Down 11.5%
ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating) was down 11.5% during mid-day trading on Friday . The company traded as low as $5.68 and last traded at $5.69. Approximately 35,224 shares changed hands during trading, a decline of 97% from the average daily volume of 1,358,237 shares. The stock had previously closed at $6.43.
免疫生物公司(納斯達克代碼：IBRX-GET評級)週五午盤下跌11.5%。該公司股價低至5.68美元，最新報5.69美元。約35,224股股票在交易中易手，較1,358,237股的日均成交量下降了97%。該股此前收盤價為6.43美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of equities analysts have issued reports on IBRX shares. Piper Sandler decreased their price target on ImmunityBio from $20.00 to $10.00 in a research note on Friday, May 27th. Jefferies Financial Group started coverage on ImmunityBio in a research note on Wednesday, August 3rd. They set a "buy" rating and a $8.00 price target for the company.
許多股票分析師已經發布了關於IBRX股票的報告。派珀·桑德勒在5月27日星期五的一份研究報告中將免疫生物的目標價從20.00美元下調至10.00美元。傑富瑞金融集團在8月3日星期三的一份研究報告中開始了對免疫生物的報道。他們為該公司設定了“買入”評級和8.00美元的目標價。
ImmunityBio Stock Performance
免疫生物股票表現
The firm has a 50 day moving average price of $4.46 and a two-hundred day moving average price of $4.48.
該公司的50日移動均線價格為4.46美元，200日移動均線價格為4.48美元。
Institutional Investors Weigh In On ImmunityBio
機構投資者參與免疫生物
About ImmunityBio
關於免疫生物
(Get Rating)
(獲取評級)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.
免疫生物公司是一家臨牀階段的生物技術公司，致力於開發補充、利用和放大免疫系統以戰勝癌症和傳染病的療法和疫苗。它提供免疫治療和細胞治療平臺，包括抗體細胞因子融合蛋白、合成免疫調節劑、疫苗技術、自然殺傷細胞和適應性(T細胞)免疫系統。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on ImmunityBio (IBRX)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免費獲取StockNews.com關於免疫生物的研究報告(IBRX)
- 股市：紅海中的三座強國
- 第四季度值得考慮的3家銀行
- 有什麼辦法可以治癒Teladoc股票的問題嗎？
- 沒有人告訴這三隻股票這是下跌的一週
- MarketBeat：回顧一週9/12-9/16
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得新聞和免疫評級《生物日報》-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對免疫生物公司和相關公司評級的每日簡要摘要。